Video Library
Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases
In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.
Prof. Deepak L. Bhatt
First published: September 10, 2024
Video Library
ESC Congress 2022 Highlights – Part One
Watch part one of the ESC Highlights Video. In this video Prof. Lale Tokgözoğlu summarizes some of the exciting findings that were presented in ESC 2022.
Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu
First published: November 1, 2022
Video Library
ESC Congress 2022 Highlights – Peer-to-Peer Discussion – Part Two
Watch part two of the ESC Highlights Video wherein Prof. Christopher Cannon and Prof. Lale Tokgözoğlu discuss results of some exciting trials highlighting the significance of Lp(a), PCSK9 inhibitors, patient adherence and compliance.
Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu
First published: November 1, 2022
Video Library
Impact of lipid therapies on coronary disease
In this KOL masterclass on demand video, Prof. Stephen Nicholls will discuss the impact of intensive lipid lowering strategies (statins, evolocumab, alirocumab) on plaque phenotype and progression.
This masterclass on-demand video is designed for health care professionals (cardiologists, lipidologists, diabetes specialists, neurologists) who are interested in learning more on the results of the latest clinical trials (GLAGOV, HUYGENS, PACMAN-AMI) on coronary disease.
Prof. Stephen Nicholls
First published: July 7, 2022
Video Library
Peer-to-Peer Discussion: Novel lipid-lowering therapies
Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.
To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.
Prof. Christopher Cannon, Prof. Kausik Ray
First published: January 10, 2022